Clinical trial NCT03303690: AS: Ankle Spacer for Talar Osteochondral Defects
Official title: A Prospective Trial on the Clinical Efficacy of the Ankle Spacer for the Surgical Treatment of Large, Multiple, Cystic and Secondary or Tertiary Osteochondral Defects of the Talus
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Osteochondral Defect of Talus
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
First posted: 2017-10-06
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: By means of the Ankle Spacer patients will be implanted, the clinical and radiological results of which will be prospectively recorded and analyzed at different points in time.

Detailed description: Ankle sprains can result in talar osteochondral defects (OCDs) which have a significant impact on the quality of life of patients. When these OCDs are of large nature (anterior-posterior or medial-lateral diameter \>1.5cm in diameter), cystic, have failed prior surgical treatment, or when there are multiple present on the talar articular surface, surgical care by means of fixation or bone marrow stimulation is contra-indicated. An ankle arthrodesis or fusion can be considered, but this results in functional limitation due to a decreased range of motion (ROM). In order to serve for a bone sparing prosthesis procedure, preserve range of motion, optimize physical functioning and to resurface the talus, the Ankle Spacer has been developed. It is a one-piece implant system that replaces the articulating upper talus surface of the tibio-talar joint, and offers several implant sizes in order to fit to the different talus sizes. It is anatomically designed to the native upper talus surface to provide an optimal fit to the distal articular surface. It has a rough titanium plasma spray (TPS) coated under surface with two posts and spikes for implant fixation. The rough surface enables secondary fixation by means of bone ingrowth and the spikes at the posterior part of the prosthesis allowing for optimal adherence of the implant and for minimal iatrogenic damage upon fixation. By these means, the anatomical situation and the natural congruency of the ankle joint are mirrored to a optimal extent. Despite the fact that no clinical trials have been published on this specific implant, it is hypothesized that the 5-year postoperative clinical outcomes concerning pain and prosthesis survival will be considered good.

Eligibility criteria: Inclusion Criteria:

* age ranging from 18 to 80 years
* talar osteochondral defect (multiple degenerative talar cysts present, and/or prior failed surgical treatment and/or multiple defects and/or large (\>15mm))
* willing to receive surgical implantation of the Ankle Spacer
* has been informed of the nature of the study and provided written consent
* The subject and treating physician agree that the subject will return for all required post-procedure follow-up visits
* failed previous conservative treatment
* complaints for at least 6 months

Exclusion Criteria:

* -severe ankle malalignement.(\> 5° varus/valgus).
* fracture \< 6 months - tendinitis - diabetes mellitus / rheumathoid arthritis
* advanced osteoporosis
* grade two or higher (Kellgren-Lawrence-Score) ankle joint degeneration on the tibia side.
* any ankle deformation that does not allow proper rasping of the cartilage and/or proper seating of the desired sized implant, as described in the surgical technique.
* blood supply limitations and previous infections, which may retard healing.
* foreign-body sensitivity. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation.
* active infection or blood supply limitations.
* conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period, including severe neuro-arthropathy.
* pathological conditions, such as insufficient quantity or quality of bone (e.g., cystic changes or severe osteopenia), which may compromise implant fixation.
* currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
* Inability to be brought back to the surgery site for long term follow-up evaluations or the subject is unwilling to fill out the appropriate evaluation forms
* adiposity grade I (BMI \> 30 kg/m2)

Primary outcomes:
measure: NRS during walking/weightbearing
timeFrame: 2 years postoperatively
Secondary outcomes:
measure: NRS at rest and during stairclimbing
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: NRS during stairclimbing
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: AOFAS (American Orthopedic Foot and Ankle Score)
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: FAOS (Foot and Ankle Outcome Score)
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: SF-36 (Short-Form 36) Physical Component Scale
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: SF-36 (Short-Form 36) Mental Component Scale
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: ROM (range of motion)
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: demographic data: sex
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: demographic data: age
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
measure: Radiographic evaluation
timeFrame: pre-operatively, follow-ups at 2 weeks, 6 weeks, 3 months, 6 months, 1,2,3,4,5 year postop.
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Academic Medical Center
state: Noord Holland
Study officials:
affiliation: Academic Medical Center (AMC Amsterdam)
name: G.M.M.J. Kerkhoffs, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: